The Accelerating Access Initiative (AAI), begun in 2000, is a partnership between UNAIDS, the World Health Organization (WHO), the UN Children's Fund (UNICEF), the UN Population Fund (UNFPA), the World Bank and seven research-based pharmaceutical companies (Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc., Roche, Tibotec (an affiliate of Johnson & Johnson) and ViiV Healthcare, which combines the HIV medicine operations of GlaxoSmithKline, Pfizer.
The Abbott Fund is partnering with several organizations to expand access to health care for mothers and children affected by HIV/AIDS in developing countries. Since 2001, more than 1 million children and adults have received services in Burkina Faso, India, Kenya, Malawi, Romania, Tanzania and Uganda. The Abbott Fund supported the Baylor College of Medicine in establishing a pediatric HIV/AIDS treatment program in Romania that reduced the death rate for children with HIV in the program by more than 90%.
Children in Vietnam are afflicted with some of the most severe forms of malnutrition, an unacceptable reality caused by limited access to nourishing food and a lack of nutritional education. According to UNICEF, more than 25% of Vietnamese children under five are underweight and more than 10% of Vietnamese children suffer from vitamin A deficiency. To help improve the overall nutritional health of children in rural areas of Vietnam, the Abbott Fund is working with AmeriCares to support the Giao-Diem Humanitarian Foundation.
Since 2007, Partners In Health coordinated a heart failure treatment and prevention initiative in two district hospitals in Rwanda (Rwinkwavu and Kirehe). The heart failure treatment program supports nurse-driven clinics providing routine heart exams and medications, daily patient home visits by community health care workers, and collaboration with cardiac surgical teams. In 2008, Abbott provided the Cardiac Health Initiative with Abbott's i-STAT handheld analyzer, which provides clinic staff with rapid results for commonly ordered medical tests.
Malnutrition is a significant contributor of early morbidity and mortality among young children in Cambodia. According to UNICEF, the mortality rate for children under five increased from 115 per 1,000 live births in 1990 to 143 in 2005; nearly 45% of all children under five are underweight. Since 2006, Abbott and the Abbott Fund have partnered with Direct Relief International and Angkor Hospital for Children in Siem Reap in an effort to reverse these troubling trends.
Years of civil war have had a devastating impact on the health and lives of women and children in the Democratic Republic of Congo. The country suffers from one of the highest maternal mortality rates in the world, at 1,100 deaths per 100,000 live births, the third highest infant mortality rate in Africa at 129 deaths per 1,000 live births, and 67% of pregnant women are anemic.
According to the World Health Organization, Afghanistan has the second highest maternal mortality rate in the world, with 1,900 deaths per 100,000 live births. In addition, one in four Afghan children will not live to see their fifth birthday. To improve the lives of women and children in Afghanistan, Abbott and the Abbott Fund are partnering with the Afghan Institute of Learning (AIL) and Direct Relief International to help reverse the country's high maternal mortality rate, and increase the survival and overall health of infants and children.
The Abbott Fund and the Government of Tanzania have formed a unique public-private partnership to modernize the country's health care system. The Abbott Fund has invested more than USD 60 million aimed at enhancing access to health care on a national scale. Today, one in three Tanzanians with HIV taking antiretroviral therapy receive services at a facility that has benefited from Abbott Fund support. Work is being conducted across the country, including significant work at Muhimbili National Hospital, the country's leading teaching and referral hospital.
Abbott has a longstanding commitment to the fight against HIV/AIDS and has implemented five practical measures to ensure the company's medicines are as broadly available as possible: Innovation with the Needs of the Developing World in Mind: Abbott developed the lopinavir/ritonavir tablet, the only co-formulated protease inhibitor tablet that does not require refrigeration and can be taken with or without food - two important advances in delivering HIV medicine, especially in developing countries.
Since 2006, Abbott and the Abbott Fund have partnered with Direct Relief International to support the education and outreach activities of Centro Vivir Con Diabetes, a non-governmental organization dedicated to low-income adults and children living with both type I and type II diabetes in Cochabamba, Bolivia. The Abbott Fund has provided grants to support diabetes education, expand public outreach campaigns, train health care personnel in diabetes management, and establish and expand the number of core diabetes educators.
Since 2003, the ACCESS Project has been devoted to analyzing and improving access to effective malaria treatment in Tanzania. Main interventions have included social marketing campaigns to inform the population on causes, symptoms and appropriate treatment of malaria, training and supportive supervision of health personnel and the establishment of licensed private drug stores. One of the initiative's achievements has been the development of a general analytical and planning framework on the issue of access, which can also be applied to other diseases and contexts.
The Aeras Global TB Vaccine Foundation helps develop new concepts and tools to control the global TB epidemic. Today the organization focuses solely on developing new vaccines against TB and ensuring their availability to all who need them.
African Comprehensive HIV/AIDS Partnerships (ACHAP) was established to enhance Botswana's response to the HIV/AIDS epidemic through a comprehensive approach to prevention, care, treatment and support. Additionally, ACHAP works to strengthen Botswana's health care system, promote behavior change and support grassroots efforts to tackle HIV/AIDS.
In 2006, Novartis' Consumer Health and Sandoz divisions launched an initiative in India to address the neglected health needs of rural populations. The Arogya Parivar (healthy family) program started with pilot sites in the states of Uttar Pradesh and Maharashtra. It combines healthcare education with access to affordable medicines through local pharmacies. The initiative aims to build a sustainable business that improves access to healthcare among the underserved millions in rural India by providing locally available and affordable health solutions.
One of the biggest obstacles to improving the health of women and children, the aim of UN Millennium Development Goals 4 and 5, is inadequate primary care capacity. Pfizer has been working the Arpana Research and Charitable Trust, an NGO operating in rural and urban India, since 2002. Pfizer's funding and in-kind support is now focused on building technical capacity at Arpana Hospital, a 135-bed facility in rural Haryana, and in the NGOs' operations in two other Indian States.
Associação Saude Da Familia (ASF) mobilizes community support in poor favelas in Sao Paulo, Brazil, to protect young people from unwanted pregnancies and sexually transmitted diseases. This includes raising awareness and spreading information about HIV/AIDS. In these teeming slums, where drugs and violent crime are a constant reminder of the fragility of civil societies, ASF works with local community leaders, and municipal and state governments, to implement its programs to encourage safer and healthier behaviour.
AstraZeneca and the African Medical and Research Foundation (AMREF) have been working together since 2004. The partnership initially focused on TB in the Eastern Cape province of South Africa. In 2006, AstraZeneca extended its commitment to support AMREF in strengthening healthcare systems and integrating management of TB, HIV and malaria programs in Uganda, where there is a high burden of all three diseases. AstraZeneca is one of a few organizations involved in this integrated approach.
Since 2006, AstraZeneca has supported the Red Cross in its community-based work to help reduce TB incidence and improve the quality of life of people affected by TB and TB/HIV in sub-Saharan Africa. With AstraZeneca's support, the South African Red Cross is delivering improved care and support to people living with TB or TB/HIV in 10 provinces, including the KwaZulu Natal, Western Cape, Eastern Cape, Limpopo, Gauteng and Free State.
AstraZeneca's long-standing partnership with the British Red Cross Society is focused on helping the international Red Cross and Red Crescent movement to deliver community-based programs in Central Asia which encourage people to seek early diagnosis, Improve patient compliance, provide care in the home, promote TB and TB/HIV awareness/education and address the stigma associated with the diseases.
The AstraZeneca Bangalore Research Institute in India combines TB research and manufacturing capabilities.
In Ethiopia, AstraZeneca has been working since 2005 to help build local capability in managing breast cancer - the second most common cancer among young women in the country. The company's partner in this project is Axios, an organization that works with the private sector to advance healthcare in developing countries. In the developing world, the incidence of cancer is increasing. It is predicted that 20 million more people will be diagnosed by 2010, and 70% will live in countries that between them will have less than 5% of the resources for cancer control.
AstraZeneca's product donation and patient assistance programs make its medicines available to those who cannot afford them, either free-of-charge or at reduced prices. In 2009, AstraZeneca donated a total of USD 786 million in product. The total spend on charitable contributions was USD 96 million (this includes the figure for 'employee commitment' which is defined as 'total company spend to support employee working days committed to company endorsed community activities'. The Employee Commitment figure does not represent a value assigned to the employee time committed).
In 2002, Bayer HealthCare agreed to supply - at no cost and for an initial five-year period - as much of the sleeping sickness medicine Germanin (suramin) as the World Health Organization (WHO) determines is needed to eliminate the disease. The initial donation comprised 50,000 ampoules. Bayer is also in favor of supporting an 'Integrated Sleeping Sickness Initiative' fostered by a broad base of institutions and covering all aspects of the disease from infection, diagnosis and therapy to prevention.
In 2007, Bayer HealthCare, in partnership with local authorities and charitable organizations, started the first patient access program for Nexavar (sorafenib) in Asia for the treatment of renal cell carcinoma and is planning further implementation in this region. Bayer HealthCare donates its medicine Nexavar to facilitate access for patients who cannot afford the cost of a full course of therapy. In 2008, Bayer HealthCare initiated another patient access program for Nexavar, for the treatment of hepatocellular carcinoma, after its approval for this indication.
In April 2007, Bayer signed a new agreement to provide the World Health Organization (WHO) with 2.5 million Lampit tablets and additional funding for the distribution of the drug. The latest agreement assures the supply of Lampit until 2012. To widen access of patients to affordable medicines, Bayer HealthCare signed agreements with the World Health Organization (WHO) in 2004 and 2005 for donations of its medicine Lampit (nifurtimox) to combat Chagas disease, the form of sleeping sickness found in Latin America.